

Title	Vitamin D in pregnancy: Where we are and where we should go
Authors	Kiely, Mairead E.;Wagner, C. L.;Roth, D. E.
Publication date	2020-04-14
Original Citation	Kiely, M. E., Wagner, C. L. and Roth, D. E. (2020) 'Vitamin D in pregnancy: Where we are and where we should go', Journal of Steroid Biochemistry and Molecular Biology, 201, 105669 (9pp). doi: 10.1016/j.jsbmb.2020.105669
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1016/j.jsbmb.2020.105669
Rights	© 2019, Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC BY-NC-ND 4.0 license. - https://creativecommons.org/licenses/by-nc-nd/4.0/
Download date	2024-06-15 13:44:49
Item downloaded from	https://hdl.handle.net/10468/10311

Manuscript Details

Manuscript number	SBMB_2019_585_R1
Title	Vitamin D in pregnancy: Where we are and where we should go
Article type	Review Article

Abstract

Vitamin D deficiency has been widely reported among pregnant women and infants around the world. Women with low sun exposure, high BMI, low vitamin D intakes and socioeconomic disadvantage with poor quality diets are at greatest risk of vitamin D deficiency, leading to very low serum concentrations of 25-hydroxyvitamin D (25(OH)D) in their offspring and an increased risk of nutritional rickets. Many observational studies, supported by compelling in vitro and in vivo data, have generated evidence suggesting that low vitamin D status in pregnancy may also contribute to the risk of adverse perinatal outcomes including hypertensive disorders (e.g., preeclampsia), fetal growth restriction, and preterm birth. However, the few large randomized controlled trials (RCTs) conducted to date have generated conflicting evidence for a role of vitamin D supplementation in improving perinatal outcomes. Vitamin D supplementation policies during pregnancy and implementation of policies vary within and between jurisdictions. Regulatory authorities have cited insufficient evidence to establish pregnancy-specific targets for serum 25(OH)D concentrations or prenatal vitamin D intake that effectively reduce the risks of adverse perinatal and infant outcomes. This paper arises from a Debate on Vitamin D Requirements during Pregnancy, held at the 22nd Vitamin D Workshop, 2019. From varied perspectives, our objectives were to evaluate the evidence for: vitamin D metabolism in pregnancy and the prevalence of gestational vitamin D deficiency worldwide; the translation of laboratory research findings to clinical studies on the role of vitamin D in perinatal health; the challenges of designing and conducting clinical trials to establish prenatal vitamin D requirements; and results to date of major large RCTs of prenatal vitamin D supplementation. Lastly, we explored potential next steps towards generating robust clinical data in this field to address both public health protection and patient care.

Keywords	Vitamin D; Vitamin D Requirements; Pregnancy; Perinatal health; Vitamin D status
Corresponding Author	Mairead E. Kiely
Corresponding Author's Institution	University College Cork
Order of Authors	Mairead E. Kiely, Carol Wagner, Daniel Roth
Suggested reviewers	Martin Hewison, James Fleet

Submission Files Included in this PDF

File Name [File Type]

Response to Reviewers Comments_03 13 20.docx [Response to Reviewers]

Hlghlights.docx [Highlights]

Controversies in Vitamin D Revised Final Clean.docx [Manuscript File]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

Controversies in Vitamin D

Vitamin D in pregnancy: Where we are and where we should go

M.E. Kiely ^{1,2}, C.L. Wagner ³, D.E. Roth ⁴

¹ Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Ireland, ² INFANT Research Centre, University College Cork, Ireland, ³ Division of Neonatology, Medical University of South Carolina, Charleston, SC 29425, United States, ⁴ Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.

Abstract

Vitamin D deficiency has been widely reported among pregnant women and infants around the world. Women with low sun exposure, high BMI, low vitamin D intakes and socioeconomic disadvantage with poor quality diets are at greatest risk of vitamin D deficiency, leading to very low serum concentrations of 25-hydroxyvitamin D (25(OH)D) in their offspring and an increased risk of nutritional rickets. Many observational studies, supported by compelling *in vitro* and *in vivo* data, have generated evidence suggesting that low vitamin D status in pregnancy may also contribute to the risk of adverse perinatal outcomes including hypertensive disorders (e.g., preeclampsia), fetal growth restriction, and preterm birth. However, the few large randomized controlled trials (RCTs) conducted to date have generated conflicting evidence for a role of vitamin D supplementation in improving perinatal outcomes. Vitamin D supplementation policies during pregnancy and implementation of policies vary within and between jurisdictions. Regulatory authorities have cited insufficient evidence to establish pregnancy-specific targets for serum 25(OH)D concentrations or prenatal vitamin D intake that effectively reduce the risks of adverse perinatal and infant outcomes. This paper arises from a Debate on Vitamin D Requirements during Pregnancy, held at the 22nd Vitamin D Workshop, 2019. From varied perspectives, our objectives were to evaluate the evidence for: vitamin D metabolism in pregnancy and the prevalence of gestational vitamin D deficiency worldwide; the translation of laboratory research findings to clinical studies on the role of vitamin D in perinatal health; the challenges of designing and conducting clinical trials to establish prenatal vitamin D requirements; and results to date of major large RCTs of prenatal vitamin D supplementation. Lastly, we explored potential next steps towards generating robust clinical data in this field to address both public health protection and patient care.

Key-words: Vitamin D; Vitamin D Requirements; Pregnancy; Perinatal health; Vitamin D status

1 *Introduction*

2 Pregnancy and infancy are life-stages for which evidence of low vitamin D status is
3 widespread but the evidence basis for setting dietary requirements for vitamin D is weakest
4 (Institute of Medicine, 2011). Prevention of low vitamin D status is required to reduce the
5 risk of nutritional rickets among children and adolescents and osteomalacia in adults, which
6 can have severe and lasting consequences for bone growth and skeletal integrity (Munns et al
7 2016). The recent discovery of non-skeletal roles for vitamin D has changed the landscape
8 considerably and mechanistic studies have elaborated the molecular roles of vitamin D in
9 many systems, for example, immunity (Adams and Hewison, 2008, Chun et al., 2014b).
10 Modulation of the intrauterine immune environment by vitamin D has been implicated in
11 adverse perinatal outcomes, including recurrent pregnancy loss, preeclampsia and
12 spontaneous preterm birth (Liu and Hewison, 2012, Tamblyn et al., 2015). Indications are
13 that early pregnancy may be the critical window for prevention of these adverse events.

14 The definition of healthy vitamin D status during pregnancy, typically indicated by
15 circulating concentrations of 25-hydroxyvitamin D (25(OH)D), is the subject of intense
16 debate, which has been challenged by a lack of data from well-powered, well-controlled trials
17 in pregnant women, particularly among women with low circulating 25(OH)D at baseline.
18 Multiple systematic reviews of the role of vitamin D supplementation during pregnancy have
19 been published but these have lacked data from substantial trials and there is no consensus as
20 to whether physiological requirements for 25(OH)D are higher during pregnancy than in non-
21 pregnant adults (Roth et al., 2017). It is also worth noting that trials and reviews of trials have
22 framed the question around the benefit of *additional* vitamin D supplementation during
23 pregnancy (using a pharmacological model of intervention regardless of baseline status)
24 rather than the role of *sufficient vitamin D to support healthy pregnancy from the outset*.

25 A Debate on the controversial topic of Vitamin D Requirements during Pregnancy was held
26 at the 22nd Vitamin D Workshop, 2019. Our objectives were to evaluate the current state of
27 the evidence for:

- 28 • vitamin D metabolism in pregnancy, and the prevalence of gestational vitamin D
29 deficiency worldwide;
- 30 • the translation of laboratory research findings to clinical studies on the role of vitamin
31 D in perinatal health;
- 32 • the challenges of designing and conducting clinical trials to establish prenatal vitamin
33 D requirements; and,
- 34 • results to date of major large RCTs of prenatal vitamin D supplementation.

35 The three authors hold some shared and some divergent views on the core issues discussed
36 and provided their perspectives on these issues. Our common goal was to explore potential
37 next steps towards generating robust clinical data in this field to address both public health
38 protection and patient care. In the presentation of the evidence in this paper, we aimed to
39 convey the plurality of divergent viewpoints rather than present a unified or consensus
40 statement.

41 *Low vitamin D status is common among pregnant women and infants*

42 A key question to be addressed is whether the prevalence of 25(OH)D <25-30 and <50
43 nmol/L is higher among pregnant women than among other population groups. Saraf and
44 colleagues (2016) estimated the global prevalence of 25(OH)D concentrations < 50 nmol/L at
45 54% among pregnant women and 75% among newborns. Almost one in five pregnant women
46 and one in three newborns were below 25 nmol/L, placing them at increased risk of
47 developing rickets and osteomalacia. A systematic review of 25(OH)D concentrations in low-
48 and middle-income countries (LMIC) by Cashman et al (2019) reported that 29 out of the 83
49 countries included had 25(OH)D data available. Afghanistan, Pakistan, India, Tunisia, Syria,
50 the West Bank and Gaza and Mongolia were classified as “hot spots” for very low 25(OH)D
51 (<25-30 nmol/L) among women, pregnant women or infants on the basis of having a
52 prevalence in excess of 20%(Cashman et al., 2019). In low income and middle eastern
53 countries in particular, women and girls appear to have lower circulating 25(OH)D than their
54 male counterparts, probably due to clothing practices (Roth et al., 2018a, Lips et al., 2019).
55 Palacios and Gonzales (2014) described a high prevalence (>20%) of 25(OH)D <30 nmol/L
56 among pregnant women and infants, in many countries, including in South Asia and the
57 Middle East; up to 60% of women in India and 86% of infants in Iran had 25(OH)D < 30
58 nmol/L.

59 One of the challenges of interpreting global 25(OH)D data is the methodological variability
60 in analytical methods and data reporting, which can be particularly challenging for maternal
61 samples (Best et al 2019). The relatively low uptake, and low rate reporting of laboratory
62 performance of users of quality assurance systems, such as DEQAS (Carter et al 2017), leads
63 to a lack of transparency. Application of the NIH Vitamin D Standardization Protocol
64 (VDSP) should be used to standardize 25(OH)D data if serum aliquots are available for re-
65 analysis by LC-MS/MS, using a validated statistical approach (Durazo-Arvizu et al 2017).
66 The CDC Vitamin D Standardization-Certification Program (VDSCP) is also available as an
67 avenue to achieve accreditation of 25(OH)D analysis.

68 Within temperate countries, the prevalence of vitamin D deficiency is much higher among
69 persons with darkly pigmented skin tones. Using VDSP, the ODIN project reported the first
70 internationally standardised dataset of vitamin D status and the prevalence of vitamin D
71 deficiency across Europe (Cashman et al., 2016). While the overall prevalence of 25(OH)D <
72 30 nmol/L was 13%, about twice that of the US (5.9%) (Schleicher et al., 2016) and Canada
73 (7.4%) (Sarafin et al., 2015), persons with more darkly pigmented skin tones were at much
74 higher risk than their white counterparts both in Europe and North America. As part of the
75 ODIN project, Kiely et al. (2016) analysed a pregnancy cohort of 1800 women in Ireland,
76 where there is no maternal vitamin D supplementation policy. Data from CDC-accredited
77 LC/MS-MS analysis of 25(OH)D showed that 17% were below 30 nmol/L at 15 weeks of
78 gestation; this was 49% among women of ethnic minority (Kiely et al., 2016). Among the
79 infants of this cohort, 46% of umbilical cord sera had a 25(OH)D < 30 nmol/L; this was 73%
80 among infants from women of ethnic minority (Kiely et al., 2017b).

81 *Nutritional Rickets*

82 In line with the prevalence data for 25(OH)D among mothers and newborns, it is no surprise
83 to note that the greatest burden of nutritional rickets is in Africa, Asia and the Middle East
84 (Thacher et al., 2006, Prentice, 2013). There is also evidence that while the incidence of
85 nutritional rickets is stable or decreasing among whites, it is increasing in North America and
86 Europe among immigrant populations (Creo et al., 2017). Thacher et al (2016) provided a
87 summary of nutritional rickets in immigrant and refugee children using data collected in the
88 UK, Denmark, Australia, Canada and the US. Populations most at risk were South Asian,
89 African and Middle Eastern African, with incidence rates (per 1000,000/year) up to 24 in
90 young children < 3 years and up to 4.9 among children ≤ 15 years. The stark contrast between
91 whites and ethnic minorities in western countries is highlighted in the *Global Consensus*
92 *Recommendations on Prevention and Management of Nutritional Rickets* (Munns et al.,
93 2016). Most clinical insights are gained from hospital admissions; Uday et al (2018) have
94 documented hypocalcemic dilated cardiomyopathy associated with nutritional rickets and in
95 some cases, fatal consequences. These prevalence estimates of maternal and infant 25(OH)D
96 concentrations and the resulting effects elevate vitamin D deficiency among mothers and
97 babies to the status of a serious public health problem that requires urgent action.

98

99 *Challenges in defining nutritional requirements for vitamin D during pregnancy*

100 To provide the policy context, Mairead Kiely (MK) also summarized current dietary
101 recommendations for vitamin D in in pregnant and lactating women in line with the 25(OH)D
102 concentration targets they are intended to reach. Individual intake recommendations range
103 from 5 to 15 $\mu\text{g/day}$ (200-600 IU) to achieve 25(OH)D targets of ≥ 25 to 50 nmol/L (10 to 20
104 ng/mL) (Kiely et al., 2017a). Although there is some variation between these
105 recommendations, they were all formulated based on evidence from RCTs of vitamin D
106 status and bone health outcomes. Due to a lack of evidence on which to set nutritional
107 requirements for 25(OH)D during pregnancy specifically, recommendations for vitamin D
108 intake are the same for pregnant and lactating women as non-pregnant adults.

109 *Vitamin D requirements from the perspective of vitamin D biology*

110 Carol Wagner (CW) presented data showing that unlike other times during the lifespan,
111 pregnancy involves the orchestration of events that must protect the mother while allowing
112 growth and development of the fetus. There is a delicate immune balance that nurtures the
113 allogeneic fetus, while maintaining reactivity against pathogens to the outside world (Racicot
114 et al., 2014, Mor and Cardenas, 2010, Vijayendra Chary et al., 2015a). During the first
115 trimester, a proinflammatory state allows for the invasion of the uterine wall by fetal derived
116 cytotrophoblast cells to become the placenta. Following the establishment of the maternal-
117 placental-embryonic unit, there is rapid growth of the fetus, which must occur in a state that
118 is by comparison to the earlier first stage of pregnancy, anti-inflammatory (Racicot et al.,
119 2014, Mor and Cardenas, 2010). This relatively anti-inflammatory state will last well beyond
120 the second trimester and into the third trimester, when the uterine environment becomes more
121 proinflammatory to allow the onset of labour and the expulsion of the fetus from the uterus
122 (Racicot et al., 2014, Mor and Cardenas, 2010). Dysregulation of these tightly controlled

123 biophenomena at a systemic and placental level have been considered as a
124 potential mechanism mediating pathogenesis of recurrent pregnancy loss (Ji et al., 2019)
125 preeclampsia and spontaneous preterm birth (Weiss et al., 2016, Mirzakhani et al., 2016). It is
126 postulated by many that these adverse events during pregnancy have their origins early-on in
127 pregnancy, with derangement of the critical balance in immune function (Hollis and Wagner,
128 2017b, Liu and Hewison, 2012, Tamblyn et al., 2015).

129 1,25(OH)₂D mediates gene expression via VDR and VDREs, and increased concentrations of
130 1,25(OH)₂D could have implication for gene pathways and subsequent function. In mouse
131 models of vitamin D deficiency studied early in gestation, an array of genes in the placenta are
132 upregulated and others downregulated based on maternal vitamin D status (Liu et al., 2011),
133 which find corollaries in human studies, especially following adverse pregnancy outcomes
134 such as preeclampsia (Powe et al., 2010, Robinson et al., 2010, Baker et al., 2010, Bodnar et
135 al., 2014, Mirzakhani et al., 2016). Parallel findings are noted in the upregulation of certain
136 placental genes that have been implicated in preeclampsia (Schulz et al., 2017). There are
137 studies that describe alternation in T cell phenotype associated with preterm birth (Zahran et
138 al., 2018) and recurrent pregnancy loss in women who are vitamin D deficient (Ji et al., 2019,
139 Kwak-Kim et al., 2016, Wu et al., 2018, Sharif et al., 2018). There are also non-genomic
140 calcitriol-dependent biological effects that can take place in cells, involving second messengers
141 generated by membrane-initiated signalling pathways (Novakovic et al., 2009).
142 Classic vitamin D receptor (VDR) and the membrane-associated rapid response steroid-
143 binding protein (MARRS) found in the cell membrane may bind 1,25(OH)₂D and initiate the
144 activation of numerous pathways involving various protein kinases (PKC), MAPK, PKA,
145 phosphatidyl inositol phosphate, and Ca²⁺ and chloride channels (Olmos-Ortiz et al., 2015).
146 The VDR and regulatory metabolic enzymes are expressed in both placenta and decidua,
147 indicating a potential critical point in the immunomodulation at the maternal-fetal interface
148 (Vijayendra Chary et al., 2015b). Further, activities of vitamin D response element (VDRE)-
149 containing genes can be grouped in quite diverse biological networks: bone and mineral
150 metabolism; cell life and death (comprising proliferation, differentiation and apoptosis);
151 immune function—both innate and adaptive immunity that are thought to be operational
152 during the various stages of pregnancy (Knabl et al., 2017).

153 During pregnancy, there are major adaptations in vitamin D metabolism. After conception,
154 the fertilized egg undergoes a series of reproductive cell divisions to form the three germ
155 layers—endoderm, mesoderm, and ectoderm) that give rise to different types of cells, many
156 of which express the vitamin D receptor (VDR) (Kaludjerovic and Vieth, 2010). Various
157 cells give rise to different organs through organogenesis that extends from 4 to 10 weeks of
158 gestation with the placental fully formed and functional by 4 weeks of gestation. During this
159 time of immense activity and growth, localized concentrations of vitamin D in the form of
160 25(OH)D (which crosses the placenta from the maternal side) and 1,25(OH)₂D (which is
161 synthesized by the fetus as early as 6-10 weeks of gestation) can interact with various
162 signalling systems to regulate organ development (Kaludjerovic and Vieth, 2010). As
163 mentioned, it is the placenta that permits the transfer of 25(OH)D from the mother to the
164 fetus but also the placenta through its production of 1 α -hydroxylase that local synthesis of
165 1,25(OH)₂D occurs. 1,25(OH)₂D binds to VDR in specialized cells to induce genomic and
166 nongenomic responses that stimulate organ development.

167 Focusing on 1,25(OH)₂D during pregnancy, 1,25(OH)₂D increases more than 2–3 fold in the
168 first weeks of pregnancy that appears to come mainly from maternal kidney synthesis but
169 some is placentally-derived (Bikle et al., 1984, Hollis et al., 2011, Tamblyn et al., 2018, Best
170 et al., 2019). This increase is noted in both animal models and human studies as measured by
171 RIA and LC-Tandem mass spec (LC-MS) and is accompanied by a rise in VDBP, the main
172 carrier of all vitamin D moieties with greater avidity for 25(OH)D (Bikle et al., 1984,
173 Vijayendra Chary et al., 2015a, Hollis et al., 2011)(Hollis and Wagner, 2017a, Novakovic et
174 al., 2009, Best et al., 2019). Despite this, there is no corresponding rise in 25(OH)D during
175 pregnancy (Hollis and Wagner, 2017a).

176 The increase in 1,25(OH)₂D early in the first trimester of pregnancy is linked to higher
177 Cyp27B1 (1- α -hydroxylase) activity in maternal kidney, placental trophoblasts and decidua
178 (Bikle et al., 1984, Olmos-Ortiz et al., 2015, Whitehead et al., 1981, Hollis et al., 2011).
179 Longitudinal human studies also report a progressive increase in both bound and free
180 1,25(OH)₂D concentrations (Best et al., 2019). Previous animal studies in partly and
181 completely nephrectomized rats report that this rise is mainly attributed to increased maternal
182 synthesis *per se*, rather than decreased clearance (Gray et al., 1979). This increase in
183 1,25(OH)₂D occurs at a time during pregnancy before increased fetal calcium requirements
184 manifest, increasing from ~2 mg/day in the first trimester to 100 mg/day in last trimester that
185 is continued throughout lactation. Yet, immediately after delivery, maternal calcitriol
186 concentrations return to pre-pregnancy levels, despite significant calcium requirements
187 needed during lactation (Carneiro et al., 2010, Ritchie et al., 1998). 1,25(OH)₂D
188 concentrations by 12 weeks of gestation have already increased to a mean of 180 pmol/L,
189 further increasing to around 300 pmol/L toward the end of pregnancy, compared to
190 nonpregnant control mean concentration of 91 pmol/L (Papapetrou, 2010, Ardawi et al.,
191 1997, Hollis et al., 2011). Calcitriol circulates at low levels in fetal blood, typically less than
192 50% of the maternal value (Fleischman et al., 1980, Hollis and Pittard, 1984a, Seki et al.,
193 1994, Hillman et al., 1985). Both animal models and human data suggest that 25(OH)D
194 readily crosses the placenta, with cord blood concentrations that are around 70-100% of
195 maternal concentrations (Hollis and Pittard, 1984a, Hollis et al., 2011, Best et al., 2019).
196 Calcitriol synthesis in the fetus is likely suppressed by the high serum calcium, high
197 phosphorus, and low PTH concentrations typically observed in cord blood (Kovacs, 2014).

198 It is interesting that the rise in maternal 1,25(OH)₂D during pregnancy occurs without any
199 effect on serum ionized or corrected calcium and appears to result from uncoupling of
200 1,25(OH)₂D from its well-established actions in the non-pregnant state (Hollis et al., 2011).
201 While VDBP increases concomitantly, it does not increase to the same degree as 1,25(OH)₂D
202 (Hollis et al., 2011). In addition, upregulation of *CYP27B1* mRNA in the maternal kidneys,
203 exerts characteristics of “extrarenal” production from an endocrine standpoint, such as
204 relative unresponsiveness to stimulation by PTH (except under conditions of extreme vitamin
205 D deficiency) and lack of feedback inhibition of *CYP27B1*, and thus, 1- α -hydroxylase by
206 1,25(OH)₂D itself. This increase in 1,25(OH)₂D seems to be independent of parathyroid
207 hormone (PTH), which itself remains within the normal adult range throughout pregnancy
208 (Wagner and Hollis, 2011, Haddow et al., 2011, Hollis et al., 2011). Other hormones could

209 also contribute to the bioregulation of 1- α -hydroxylase such as PTH-rP, estradiol, prolactin,
210 and placental lactogen (Ardawi et al., 1997).

211 As shown in **Figure 1** below (from Hollis et al, with permission, (Hollis et al., 2011), this
212 kinetic reaction saturation graph of 25(OH)D and 1,25(OH)₂D shows that 25(OH)D has
213 direct influence on 1,25(OH)₂D concentrations throughout pregnancy, an event which does
214 not occur during any other time during human life. It is apparent in the figure that as lower
215 concentrations of 1,25(OH)₂D increase, first order kinetics becomes zero order kinetics, with
216 a plateauing of the graph and an inflection point at 100 nmol/L (40 ng/mL) 25(OH)D—the
217 level required to optimize 1,25(OH)₂D production during pregnancy. (**Place Figure 1 near**
218 **here**)

219 Based on these findings, it is thought by some that this inflection point of 100 nmol/L may be
220 critical during pregnancy for both maternal and fetal well-being, and that attainment of this
221 threshold early-on may be key. There are data to suggest that vitamin D status early in
222 pregnancy sets the stage for vitamin D's enabling effect on immune function (Mirzakhani et
223 al., 2016, Weiss and Litonjua, 2017). In their *post hoc* analysis using multivariable log-
224 binomial regression of maternal 25(OH)D status during pregnancy, McDonnell et al reported
225 that women attaining maternal 25(OH)D concentrations ≥ 100 nmol/L compared to ≤ 50
226 nmol/L, adjusted for covariates, was associated with a reduction in the risk of preterm birth
227 by 59% (McDonnell et al., 2017).

228 With more modern scientific technological advancement, vitamin D has been shown to act on
229 innate and structural cells to promote antimicrobial defense through induction of antimicrobial
230 peptides (e.g. cathelicidin, beta-defensins) and autophagy (Liu et al., 2006, Chun et al., 2014a).
231 Bridging both innate and adaptive immunity, vitamin D also acts on myeloid dendritic cells
232 (DC) to promote a tolerogenic antigen presenting cell (APC) phenotype (Penna et al., 2007).
233 In their recent review, Hawrylowicz and Santos provide compelling evidence that vitamin D
234 reduces naïve T cell expansion, and downregulates Th1 and Th17 responses, but has variable
235 effects on Th2 responses linked to allergic disease (Hawrylowicz and Santos, 2019). These
236 interactions result in an increased frequency of human Foxp3 and IL-10 Treg *in vitro* and *in*
237 *vivo* (Penna et al., 2005, Van Der Aar et al., 2011, Nikolic and Roep, 2013, Urry et al., 2012,
238 Pfeffer and Hawrylowicz, 2018, Hawrylowicz and Santos, 2019, Jeffery et al., 2009).
239 Similarly, Vasiliou et al., in their human dust mite-allergy mouse model, showed that vitamin
240 D deficiency *in utero* led to an increased frequency of Th2 cells and reduced anti-inflammatory
241 IL-10+ T cells in the lungs (Vasiliou et al., 2014), arguing for an *in utero* process that continues
242 after birth. As noted by Hawrylowicz and Santos (Hawrylowicz and Santos, 2019), neonatal
243 and adult immunity differs, and assumptions of how vitamin D promotes protective immunity
244 in pregnancy and neonates may be distinct to effects in adults, as they note that in recently
245 published, independent vitamin D supplementation pregnancy studies that showed such
246 differences (e.g. no correlation with Foxp3) (Hornsby et al., 2018, Chi et al., 2011, Guven et
247 al., 2012). Clearly, more research is needed in this area to inform the design of more meaningful
248 clinical trials.

249

250 *Translation of laboratory findings to clinical studies*

251 Palacios (2019b) concluded that notwithstanding inconsistent reporting of adverse events,
252 vitamin D supplementation appears safe. Studies presented by CW also showed a high degree
253 of safety in both mother and fetus/neonate and later, in the offspring during longitudinal
254 follow-up studies (Hollis et al., 2011, Wagner et al., 2013b, Wagner et al., 2013a, Al-Garawi
255 et al., 2016, Chawes et al., 2016, Zhang et al., 2016, Litonjua et al., 2016, Wolsk et al.,
256 2017b, Roth et al., 2018b, Hornsby et al., 2018, Stukes et al., 2016, Kelly et al., 2019,
257 Litonjua et al., 2020). During pregnancy, there was no evidence of toxicity from high
258 25(OH)D concentrations or differences in maternal serum calcium, phosphorus, and urinary
259 calcium/creatinine ratios or adverse pregnancy outcomes among the many women who have
260 been supplemented with various combinations of vitamin D up to 110 µg/day or 1250
261 µg/week during pregnancy. There are some individuals, however, who could develop
262 toxicity if not previously diagnosed with idiopathic hypercalcemia of childhood associated
263 with Williams Syndrome (a rare genetic disorder that results in hypercalcemia with even
264 modest vitamin D supplementation due to abnormal metabolic processing (Aravena et al.,
265 2002) or from other metabolic genetic defects in vitamin D processing such as CYP24A1
266 mutations (Macdonald et al., 2020). Some studies show benefit to the pregnant woman and
267 her developing fetus with improved vitamin D status (Rostami et al., 2018) yet others do not
268 (Roth et al., 2018b), but none have shown toxicity with higher dosing within certain inclusion
269 and exclusion entry criteria. Despite the known basic science aspects of vitamin D, clinical
270 trials often fail to note differences in outcomes of supplementation during pregnancy due to a
271 number of factors listed in **Table 1 (place Table 1 near here)**.

272 Based on animal and clinical studies looking at the effect of vitamin D status at baseline early
273 in pregnancy and pregnancy outcomes (Liu et al., 2013, Dawodu et al., 2013, Chan et al.,
274 2015, Mirzakhani et al., 2016, Hewison, 2018), it would appear that the most profound
275 effects of early supplementation are seen in those with the greatest deficiency states at
276 baseline (Ganguly et al., 2018, Rostami et al., 2018). In addition, it would appear that the
277 effects are seen more notably when total circulating 25(OH)D is used as the biomarker of
278 vitamin D status during pregnancy rather than analysed on an intention-to-treat (ITT) basis.
279 Higher dose effects are more apparent in those who follow the prescribed supplementation
280 regimen and when the analysis is on a *per* protocol basis (Abercrombie et al., 2018). Another
281 consideration is that in a classic drug study with ITT analysis, the concentration of the drug in
282 question starts at 0 in both the control and treatment group(s); yet, in nutrient studies such as
283 vitamin D supplementation trials, no one starts at a concentration of zero. For this reason,
284 Heaney outlined the criteria that should be met for all nutrient studies to avoid this faulty
285 design (Heaney, 2014). The other question that continues to plague vitamin D studies is what
286 is really representative of that nutrient—in this case, vitamin D? Is it the parent compound or
287 a metabolite—25(OH)D, and is that metabolite really indicative of what is going on at the
288 cellular level? Should the metabolite be measured in its bound form or its free state
289 (Tsuprykov et al., 2019, Best et al., 2019)?

290 Best et al provide a longitudinal examination of the changes in various moieties of vitamin D
291 during adolescent pregnancy and included in their analyses free circulating 25(OH)D
292 measurement as well as VDBP (Best et al., 2019). In their analysis of 58 adolescent pregnant

293 females, the authors found that regardless of race or visit, total 25(OH)D was a stronger
294 correlate of PTH, 1,25(OH)₂D, and of the catabolite 24,25(OH)₂D than free circulating
295 25(OH)D, and neither total nor free 25(OH)D was related to serum calcium. While African
296 American pregnant girls had lower total 25(OH)D ($p < 0.0001$), their free 25(OH)D did not
297 significantly differ by race ($p = 0.2$). Of interest, in these pregnant adolescents, VDBP
298 concentration was elevated and inversely associated with the percent free 25(OH)D, but
299 measured free 25(OH)D provided no advantage over total 25(OH)D as a predictor of PTH,
300 1,25(OH)₂D, 24,25(OH)₂D, or calcium. Thus, it appears for the moment that total circulating
301 25(OH)D concentration is the best indicator of vitamin D status.

302 Other issues in assessing vitamin D status during pregnancy and its relevance to outcomes
303 includes the question of whether baseline 25(OH)D in a study represents the 25(OH)D
304 concentration circulating around the time of conception. Vitamin D supplementation as a
305 treatment is plagued with nonadherence whereas using 25(OH)D as the biomarker is not.
306 There are also issues of whether or not total circulating 25(OH)D is reflective of vitamin D
307 metabolism within the cell, especially with variable bolus dosing. Perhaps it is baseline
308 25(OH)D in early pregnancy or even preconception that is more relevant in showing the
309 effect of vitamin D status on the fetal and maternal health, but to date, no trials have
310 addressed circulating 25(OH)D at the time of conception and placental activity.

311 Systematic reviews and meta-analyses of vitamin D supplementation during pregnancy show
312 mixed results in prevention of preeclampsia and preterm birth, which may reflect timing of
313 supplementation initiation as well as study design in terms of dosing regimen and maternal
314 vitamin D status starting point (as noted in Table 1). The differences between *in vitro* and
315 animal studies results of vitamin D's role as an enabler and the often-null results of
316 randomized controlled trials challenges us to explore alternative hypotheses and to design
317 studies that integrate these divergent findings.

318 Another factor that could potentially affect study results includes estimation of sample size.
319 On what do we base the sample size of a clinical trial? Is it anticipated treatment effects such
320 as preeclampsia, hypertension, gestational diabetes, or changes in a particular relevant
321 biomarker such as T cell phenotype? Another question is when in pregnancy do you look for
322 effect? What biomarker is most appropriate? Should sample size be based on VDBP
323 genotype, specific SNPs or ethnicity, all of which affect vitamin D metabolism? These
324 questions impact study design but also data analysis. Such questions influence clinical study
325 design and create limitations in our ability to interpret the data in a meaningful manner. As
326 has been the case with the advent of scientific inquiry, the basis for what we prescribe
327 clinically must have a demonstrated rationale that befits the data and the laboratory, and
328 which can be translated to bedside practices with continued meaning and relevance. Without
329 study design that incorporates the nature of the system—in this case a hormonal system that
330 has many functions—we will fail to see benefit and make conclusions that might be
331 premature or biased. Through careful understanding of cellular mechanisms that may be
332 influencing its demonstrated effect and a broader systems-based approach across mother,
333 placenta and fetus, we will move closer to a greater understanding of the dynamic effect of
334 vitamin D during pregnancy on both the mother and her developing fetus.

335 *Alternative perspective based on evidence from published RCTs of prenatal vitamin D*
336 *supplementation*

337 While acknowledging the well-justified enthusiasm for the potential benefits of improving
338 vitamin D status in the prenatal period, Dan Roth (DR) presented a summary of selected
339 high-quality RCTs showing insufficiently convincing evidence to merit widespread changes
340 to clinical practice guidelines or policy (Roth et al., 2018a). As of the end of 2019, the World
341 Health Organization (WHO) advises that, “vitamin D supplementation is not recommended
342 for pregnant women to improve maternal and perinatal outcomes” (World Health
343 Organization, 2016). While there is little doubt that prenatal vitamin D supplementation
344 improves maternal and fetal vitamin D status in a dose-dependent manner, the clinical
345 benefits to the mother and baby remain a subject of debate (Palacios et al., 2019b, Roth et al.,
346 2017, Palacios et al., 2019a). The question is whether *additional* vitamin D during
347 pregnancy, over and above that required by a non-pregnant woman, is required. To illustrate
348 how prenatal vitamin D RCTs have so far failed to provide robust evidence of clinical
349 benefits, it is instructive to consider five published blinded RCTs that each included at least
350 500 enrolled women, were generally of high-quality, and for which publication in reputable
351 journals suggests they underwent thorough peer review (**Table 2**) **Place Table 2 near here.**
352 None of these five trials individually demonstrated a beneficial effect of the vitamin D
353 intervention on their primary outcomes, as reported in the original trial publications (Table
354 3). For other secondary outcomes of interest (e.g., birth weight, gestational age at birth or
355 preterm, neonatal or infant hospitalization, or gestational hypertension or preeclampsia), none
356 of these trials provided strong evidence of benefits of vitamin D (i.e., either the outcome was
357 reported and the effect was null or non-significant, or the outcome was not reported) (Roth et
358 al., 2018b, Litonjua et al., 2016, Cooper et al., 2016, Chawes et al., 2016, Hollis et al., 2011).
359 Importantly, these trials reported adverse event monitoring and none have raised major safety
360 concerns, so the overall inference is that prenatal vitamin D supplementation safely raises
361 25(OH)D without clearly providing other benefits to pregnant women and babies.

362 However, further efforts to unpack the results of some of these trials have led to alternative
363 interpretations based on sub-group effects, post-hoc secondary analyses, and longer-term
364 follow-up studies. For example, in their original trial report, Hollis et al. (2011) did not find
365 any significant differences in maternal and neonatal clinical outcomes (Hollis et al., 2011);
366 however, in a post-hoc analysis adjusting for race, published in 2013, Hollis and Wagner
367 wrote that, “the data from our RCT strongly suggest that vitamin D supplementation during
368 pregnancy can significantly decrease complications of pregnancy including primary
369 caesarean section ($p=0.046$), hypertensive disorders of pregnancy ($p=0.05$) and comorbidities
370 of pregnancy ($p=0.03$)” (Hollis and Wagner, 2013). This particular interpretation of the trial
371 continues to be cited as direct evidence of the clinical benefits of high-dose prenatal vitamin
372 D supplementation (Hollis, 2019). In the primary report of the MAVIDOS trial, a planned
373 sub-group analysis indicated that vitamin D supplementation increased bone mineral content
374 in newborns delivered in the winter, in contrast to the overall null findings of the trial
375 (Cooper et al., 2016). Yet, conference presentations, press releases and news stories about
376 MAVIDOS frequently highlighted this sub-group effect and emphasized the potential
377 benefits of vitamin D (Grey and Bolland, 2016). Two of the five major trials (VDAART and

378 COPSAC) had similar primary outcomes related to early-childhood wheeze and asthma, and
379 the pooled analysis of these trials indicated that vitamin D significantly reduced the incidence
380 of asthma or recurrent wheeze in the offspring up to three years of age (Wolsk et al., 2017a).
381 However, follow-up of the children in one of the trials showed no sustained effects, such that
382 the prevalence of asthma diagnoses by age 6 years was similar between the vitamin D and
383 control groups (Brustad et al., 2019).

384 Researchers and practitioners who conduct and interpret vitamin D RCTs are faced with a
385 dilemma when the primary results of a trial conflict with – or are less convincing than – other
386 *post-hoc* or alternative analyses of the same data, especially if the latter analyses support their
387 original hypothesis. Retaining the original randomized design, including all participants in
388 the analyses, and applying an intent-to-treat approach are all strategies that serve to reduce
389 biases, but there is often an appeal to dissect the data in other ways that are believed to reveal
390 hidden truths about physiology that may be obscured by the bluntness of the RCT approach
391 (**Figure 2**). Conventional analysis of a RCT is by no means a sure-fire path to clarity, and no
392 trial is without its limitations. For example, the placebo-controlled dose-ranging RCT of
393 prenatal vitamin D in Bangladesh from Roth and colleagues was specifically designed to test
394 whether vitamin D improves infant growth in a setting where stunting is common (Roth et al.,
395 2018b). It was not designed or powered to examine effects on uncommon maternal or
396 perinatal outcomes, and it is possible that the initiation of supplementation in the 2nd trimester
397 was too late to affect some outcomes such as preeclampsia (Roth et al., 2018b). Other aspects
398 of the trial may have limited its generalizability to the broader population of Bangladeshi
399 women (e.g., perhaps trial participants were healthier than average) or to populations outside
400 of Bangladesh (e.g., perhaps the trial participants' concurrent nutritional deficiencies
401 constrained the effects of vitamin D). **Place Figure 2 near here**

402 Unfortunately, systematic reviews and meta-analyses of RCTs can further confuse rather than
403 clarify the state of the evidence, as their conclusions can only be as robust as the underlying
404 evidence on which they are based (Roth et al., 2017). For example, authors of the recent
405 update of the Cochrane Collaboration systematic review of vitamin D in pregnancy had to
406 rely on mostly small trials of low or questionable quality to draw conclusions about the
407 effects of vitamin D (versus placebo) on maternal and neonatal outcomes (Palacios et al.,
408 2019a). In summarizing one of the meta-analyses, Palacios *et al.* wrote that,
409 “supplementation with vitamin D probably reduces the risk of pre-eclampsia compared to no
410 intervention or placebo (risk ratio (RR) 0.48, 95% CI 0.30 to 0.79)” and they considered this
411 to be based on “moderate-certainty evidence” (Palacios et al., 2019a). This conclusion is
412 reiterated prominently in the abstract and plain-language summary, and if true, would be of
413 considerable public health importance. However, scrutiny of the four trials on which this
414 finding was based reveals the weakness of the conclusion. The aggregated sample size was
415 only 499 women (Palacios et al., 2019a), far lower than what would be required in a primary
416 prevention trial designed for precise estimation of effects of a prenatal intervention on
417 preeclampsia. Only one of the four trials reported having any type of prospective
418 ascertainment protocol and standardized case definition for preeclampsia (Behjat Sasan et al.,
419 2017), and all of the published trial reports lack sufficient information to confidently establish
420 the reliability of their findings (Asemi et al., 2013, Sablok et al., 2015, Behjat Sasan et al.,

421 2017, Naghshineh and Sheikhaliiyan, 2016). Furthermore, reviews that incorporated other
422 trials (including those in which control groups received a low-dose of vitamin D) do not
423 support a beneficial effect of additional vitamin D for prevention of preeclampsia, at least not
424 beyond the amount in conventional prenatal multiple micronutrient supplements (5-15
425 µg/day) (Palacios et al., 2019b, Roth et al., 2017).

426 To date, there have not been *any* rigorous and adequately powered RCTs of prenatal vitamin
427 D supplementation for the prevention of hypertensive diseases of pregnancy or other adverse
428 maternal outcomes (Palacios et al., 2019b, Roth et al., 2017, Palacios et al., 2019a). Authors
429 of reviews or commentaries may conclude that vitamin D prevents pregnancy complications
430 if their meta-analysis was methodologically flawed (e.g., biased study selection, errors in data
431 abstraction) (Fogacci et al., 2019) or focused entirely on observational studies that cannot
432 provide evidence of causal effects (Tous et al., 2019, Zhou et al., 2017, Yuan et al., 2019). In
433 a recent article, Hollis recently wrote that, “Most of these clinical trials have validated the
434 positive effects of prenatal vitamin D on birth outcomes ...,” (Hollis, 2019) citing four
435 published articles to support his claim: 1) an Iranian study that reported a lower frequency of
436 preeclampsia, preterm delivery and adverse pregnancy outcomes at a hospital that conducted
437 screening for vitamin D deficiency and provided supplementation, compared to a control
438 hospital in another city (Rostami et al., 2018) (limitations of this study were highlighted in a
439 letter to the editor (Shub and McCarthy, 2019)); 2) a secondary analysis of VDAART that
440 examined asthma/wheeze outcomes but did not report on any birth outcomes (Wolsk et al.,
441 2017b); 3) another secondary analysis of VDAART that found there was no effect of vitamin
442 D supplementation on preeclampsia risk based on the RCT design, but did find an association
443 between 25(OH)D and preeclampsia using a cohort analysis (Mirzakhani et al., 2016); and, 4)
444 an observational study of the association between 25(OH)D and preterm birth (McDonnell et
445 al., 2017). There are certainly many studies suggesting that prenatal vitamin D
446 supplementation *may* have benefits, including some small RCTs; however, an unbiased
447 assessment must take stock of the entire body of evidence, taking into account study design
448 and quality.

449 *A pragmatic approach - setting the maternal vitamin D requirement to safeguard the fetal*
450 *skeleton by targeting threshold 25-hydroxyvitamin D concentrations*

451 MK proposed the possibility that given the various determinants of perinatal outcomes,
452 including personal, genetic and healthcare factors, as well as overall diet and nutrition, it may
453 be a too tall order to expect a single nutrient intervention to deliver dramatically improved
454 outcomes. This may be true both in low resource settings, where malnutrition is common, or
455 where there are no maternal or neonatal supplementation policies, but also in countries with
456 well-nourished, healthy mothers who have 25(OH)D status at baseline in excess of 50 nmol/L
457 and excellent obstetric care. Irrespective of the potential benefits of *additional* 25(OH)D to
458 enable the establishment and maintenance of a healthy pregnancy, the complete dependence
459 of the fetus and newborn infant on maternal 25(OH)D concentrations has been consistently
460 reported (Hollis and Pittard, 1984b). It is widely accepted that at minimum, very low
461 25(OH)D (<25-30 nmol/L) during pregnancy should be prevented to protect fetal skeletal
462 development (Munns et al., 2016). As cord 25(OH)D concentration is usually lower than the

463 corresponding maternal concentration (Hollis and Pittard, 1984b) and others, prevention of
464 maternal 25(OH)D below 25-30 nmol/L may not provide fetal and neonatal protection (Kiely
465 et al., 2016). Current recommendations for vitamin D during pregnancy do not consider the
466 vitamin D requirement of newborn infants and assume the immediate availability of an
467 adequate supply from early life. Therefore, Kiely et al (2017a) proposed prevention of
468 neonatal vitamin D status <25-30 nmol/L, indicated by umbilical cord 25(OH)D, as a
469 potential target for defining maternal vitamin D requirements during pregnancy, consistent
470 with prevention of nutritional rickets (Munns et al., 2016). In a placebo-controlled dose-
471 response RCT, O'Callaghan et al (2018) reported that maintaining maternal 25(OH)D
472 concentrations \geq 50 nmol/L at the end of pregnancy ensured that cord sera were all > 25
473 nmol/L. The vitamin D₃ intake required to maintain maternal 25(OH)D > 50 nmol/L in
474 almost all mothers was 30 μ g/day (1200 IU) (O'Callaghan et al., 2018), which is twice the
475 current US and EU recommendation of 600 IU. This study confirmed suggestions from two
476 RCTs in Canada (March et al., 2015) and New Zealand (Grant et al., 2014), that although 10
477 μ g vitamin D per day may prevent maternal 25(OH)D falling below 30 nmol/L, a minimum
478 of 25 μ g/d might be needed to maintain newborn 25(OH)D at this concentration. Further
479 similar dose-response studies are required in different racial and ethnic groups and in various
480 settings to generate an inclusive estimate of maternal vitamin D requirements for the
481 prevention of neonatal deficiency. Adequate consideration of calcium intake is required in
482 these studies. Calcium is infrequently considered in RCTs of vitamin D and perinatal health
483 although its role in the calcium metabolic system and maintenance of normal PTH
484 concentrations is linked to perinatal health (Hofmeyr et al., 2014, Hemmingway et al., 2018).

485 *Conclusions*

486 Laboratory science is driving our understanding of the role of vitamin D in healthy
487 pregnancy, most recently from the perspective of immune function. At a fundamental level,
488 the role of vitamin D in skeletal development has been accepted for many years, but the
489 particular needs of pregnant women and newborn infants, a high risk sector of the population,
490 have been underserved. While clinical practice guidelines are potentially more responsive to
491 new evidence, public health nutrition recommendations are infrequently updated, creating a
492 lengthy gap between the clinical research evidence base and its translation into guidance.
493 National/international policy implementation is often slow or non-existent, contributing to a
494 wide dichotomy between the state of the art and public policy, manifested in gross
495 inequalities in health care provision and poor outcomes for at risk mothers and babies. This is
496 evidenced by the wide variation in vitamin D status and rates of nutritional rickets among at-
497 risk groups within and between countries.

498 In the face of such uncertainty, where do we go from here? Even without strong evidence
499 from RCTs, it would be reasonable and safe for public health authorities to take a population
500 approach that aims to eliminate the prevalence of 25(OH)D <30 nmol/L and facilitate
501 achievement of a personal target of 50 nmol/L, including among women of reproductive age
502 (Kiely et al., 2017a; Roth et al., 2018a). In this scenario, fortification of staple foods with
503 vitamin D (Roth et al., 2018a) and scale-up of use of antenatal multiple micronutrient

504 supplements (Sudfeld and Smith, 2019) (which include modest amounts of vitamin D) will
505 likely achieve this aim and reduce the risk of severe vitamin D deficiency.

506 To determine if higher intakes of vitamin D are required in pregnancy, the optimal strategy
507 would be to conduct a large-scale RCT of prenatal vitamin D supplementation that goes
508 beyond the scope of any previous or ongoing RCT: multi-country collaboration (including
509 both high- and lower-income settings), early first trimester (or preconception) enrolment,
510 factorial design with calcium, and designed and powered for uncommon maternal outcomes
511 (preeclampsia, intrauterine death), preterm birth, and longer-term child health outcomes
512 (including nutritional rickets). Such a trial would be financially costly and logistically
513 challenging, but should be strongly considered by an international consortium of researchers
514 and funders.

515

516 References

- 517 ABERCROMBIE, M., SHARY, J., EBELING, M., HOLLIS, B. & WAGNER, C. 2018.
518 Analysis of the NICHD Vitamin D Pregnancy Cohort on a Per-Protocol vs.
519 Intent-to-Treat Basis: The Effect of Adherence on Trial Results. *Journal of Nutrition & Food*
520 *Sciences*, 8.
- 521 ADAMS, J. S. & HEWISON, M. 2008. Unexpected actions of vitamin D: new perspectives
522 on the regulation of innate and adaptive immunity. *Nat Clin Pract Endocrinol Metab*,
523 4, 80-90.
- 524 AL-GARAWI, A., CAREY, V. J., CHHABRA, D., MIRZAKHANI, H., MORROW, J.,
525 LASKY-SU, J., QIU, W., LARANJO, N., LITONJUA, A. A. & WEISS, S. T. 2016.
526 The Role of Vitamin D in the Transcriptional Program of Human Pregnancy. *PLoS*
527 *One*, 11, e0163832.
- 528 ARAVENA, T., CASTILLO, S., CARRASCO, X., MENA, I., LOPEZ, J., ROJAS, J. P.,
529 ROSEMBERT, C., SCHROTER, C. & ABOITIZ, F. 2002. Williams syndrome:
530 clinical, cytogenetical, neurophysiological and neuroanatomic study. *Rev. Med. Child*,
531 130, 631-7.
- 532 ARDAWI, M. S., NASRAT, H. A. & HS, B. A. A. 1997. Calcium-regulating hormones and
533 parathyroid hormone-related peptide in normal human pregnancy and postpartum: a
534 longitudinal study. *Eur J Endocrinol*, 137, 402-9.
- 535 ASEMI, Z., SAMIMI, M., TABASSI, Z., SHAKERI, H. & ESMAILZADEH, A. 2013.
536 Vitamin D supplementation affects serum high-sensitivity C-reactive protein, insulin
537 resistance, and biomarkers of oxidative stress in pregnant women. *J Nutr*, 143, 1432-
538 8.
- 539 BAKER, A. M., HAERI, S., CAMARGO, C. A., JR., ESPINOLA, J. A. & STUEBE, A. M.
540 2010. A nested case-control study of midgestation vitamin D deficiency and risk of
541 severe preeclampsia. *J Clin Endocrinol Metab*, 95, 5105-9.
- 542 BEHJAT SASAN, S., ZANDVAKILI, F., SOUFIZADEH, N. & BAYBORDI, E. 2017. The
543 Effects of Vitamin D Supplement on Prevention of Recurrence of Preeclampsia in
544 Pregnant Women with a History of Preeclampsia. *Obstet Gynecol Int*, 2017, 8249264.
- 545 BEST, C. M., PRESSMAN, E. K., QUEENAN, R. A., COOPER, E. & O'BRIEN, K. O.
546 2019. Longitudinal changes in serum vitamin D binding protein and free 25-
547 hydroxyvitamin D in a multiracial cohort of pregnant adolescents. *J Steroid Biochem*
548 *Mol Biol*, 186, 79-88.
- 549 BIKLE, D. D., GEE, E., HALLORAN, B. & HADDAD, J. G. 1984. Free 1,25-
550 dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and
551 subjects with liver disease. *J Clin Invest*, 74, 1966-71.
- 552 BODNAR, L. M., SIMHAN, H. N., CATOV, J. M., ROBERTS, J. M., PLATT, R. W.,
553 DIESEL, J. C. & KLEBANOFF, M. A. 2014. Maternal vitamin D status and the risk
554 of mild and severe preeclampsia. *Epidemiology*, 25, 207-14.
- 555 BRUSTAD, N., ELIASSEN, A. U., STOKHOLM, J., BONNELYKKE, K., BISGAARD, H.
556 & CHAWES, B. L. 2019. High-Dose Vitamin D Supplementation During Pregnancy
557 and Asthma in Offspring at the Age of 6 Years. *JAMA*, 321, 1003-1005.
- 558 CARNEIRO, R. M., PREBEHALLA, L., TEDESCO, M. B., SEREIKA, S. M., HUGO, M.,
559 HOLLIS, B. W., GUNDBERG, C. M., STEWART, A. F. & HORWITZ, M. J. 2010.
560 Lactation and bone turnover: a conundrum of marked bone loss in the setting of
561 coupled bone turnover. *J Clin Endocrinol Metab*, 95, 1767-1776.
- 562 CASHMAN, K. D., DOWLING, K. G., ŠKRABÁKOVÁ, Z., GONZALEZ-GROSS, M.,
563 VALTUEÑA, J., DE HENAUW, S., MORENO, L., DAMSGAARD, C. T.,
564 MICHAELSEN, K. F., MØLGAARD, C., JORDE, R., GRIMNES, G.,

565 MOSCHONIS, G., MAVROGIANNI, C., MANIOS, Y., THAMM, M., MENSINK,
566 G. B., RABENBERG, M., BUSCH, M. A., COX, L., MEADOWS, S., GOLDBERG,
567 G., PRENTICE, A., DEKKER, J. M., NIJPELS, G., PILZ, S., SWART, K. M., VAN
568 SCHOOR, N. M., LIPS, P., EIRIKSDOTTIR, G., GUDNASON, V., COTCH, M. F.,
569 KOSKINEN, S., LAMBERG-ALLARDT, C., DURAZO-ARVIZU, R. A., SEMPOS,
570 C. T. & KIELY, M. 2016. Vitamin D deficiency in Europe: pandemic? *Am J Clin*
571 *Nutr*, 103, 1033-44.

572 CASHMAN, K. D., SHEEHY, T. & O'NEILL, C. M. 2019. Is vitamin D deficiency a public
573 health concern for low middle income countries? A systematic literature review. *Eur J*
574 *Nutr*, 58, 433-453.

575 CHAN, S. Y., SUSARLA, R., CANOVAS, D., VASILOPOULOU, E., OHIZUA, O.,
576 MCCABE, C. J., HEWISON, M. & KILBY, M. D. 2015. Vitamin D promotes human
577 extravillous trophoblast invasion in vitro. *Placenta*, 36, 403-409.

578 CHAWES, B. L., BØNNELYKKE, K., STOKHOLM, J. & ET AL. 2016. Effect of vitamin
579 D3 supplementation during pregnancy on risk of persistent wheeze in the offspring: A
580 randomized clinical trial. *JAMA*, 315, 353-361.

581 CHI, A., WILDFIRE, J., MCLOUGHLIN, R., WOOD, R. A., BLOOMBERG, G. R.,
582 KATTAN, M., GERGEN, P., GOLD, D. R., WITTER, F., CHEN, T., HOLICK, M.,
583 VISNESS, C., GERN, J. & O'CONNOR, G. T. 2011. Umbilical cord plasma 25-
584 hydroxyvitamin D concentration and immune function at birth: the Urban
585 Environment and Childhood Asthma study. *Clin Exp Allergy*, 41, 842-50.

586 CHUN, R. F., LIU, P. T., MODLIN, R. L., ADAMS, J. S. & HEWISON, M. 2014a. Impact
587 of vitamin D on immune function: lessons learned from genome-wide analysis. *Front*
588 *Physiol*, 5, 151.

589 CHUN, R. F., LIU, P. T., MODLIN, R. L., ADAMS, J. S. & HEWISON, M. 2014b. Impact
590 of vitamin D on immune function: lessons learned from genome-wide analysis. *Front*
591 *Physiol*, 5, 151-151.

592 COOPER, C., HARVEY, N. C., BISHOP, N. J., KENNEDY, S., PAPAGEORGHIU, A. T.,
593 SCHOENMAKERS, I., FRASER, R., GANDHI, S. V., CARR, A., D'ANGELO, S.,
594 CROZIER, S. R., MOON, R. J., ARDEN, N. K., DENNISON, E. M., GODFREY, K.
595 M., INSKIP, H. M., PRENTICE, A., MUGHAL, M. Z., EASTELL, R., REID, D. M.,
596 JAVAID, M. K. & GROUP, M. S. 2016. Maternal gestational vitamin D
597 supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind,
598 randomised placebo-controlled trial. *Lancet Diabetes Endocrinol*, 4, 393-402.

599 CREO, A. L., THACHER, T. D., PETTIFOR, J. M., STRAND, M. A. & FISCHER, P. R.
600 2017. Nutritional rickets around the world: an update. *Paediatr Int Child Health*, 37,
601 84-98.

602 DAWODU, A., SAADI, H. F., BEKDACHE, G., JAVED, Y., ALTAYE, M. & HOLLIS, B.
603 W. 2013. Randomized controlled trial (RCT) of vitamin D supplementation in
604 pregnancy in a population with endemic vitamin D deficiency. *J Clin Endocrinol*
605 *Metab*, 98, 2337-46.

606 FLEISCHMAN, A. R., ROSEN, J. F., COLE, J., SMITH, C. M. & DELUCA, H. F. 1980.
607 Maternal and Fetal Serum 1,25- dihydroxy vitamin D levels at term. *J of Pediatr*, 97,
608 640-2.

609 FOGACCI, S., FOGACCI, F., BANACH, M., MICHOS, E. D., HERNANDEZ, A. V., LIP,
610 G. Y. H., BLAHA, M. J., TOTH, P. P., BORGHI, C., CICERO, A. F. G., LIPID &
611 BLOOD PRESSURE META-ANALYSIS COLLABORATION, G. 2019. Vitamin D
612 supplementation and incident preeclampsia: A systematic review and meta-analysis of
613 randomized clinical trials. *Clin Nutr*.

614 GANGULY, A., TAMBLYN, J. A., FINN-SELL, S., CHAN, S. Y., WESTWOOD, M.,
615 GUPTA, J., KILBY, M. D., GROSS, S. R. & HEWISON, M. 2018. Vitamin D, the
616 placenta and early pregnancy: effects on trophoblast function. *J Endocrinol*, 236,
617 R93-r103.

618 GRANT, C. C., STEWART, A. W., SCRAGG, R., MILNE, T., ROWDEN, J., EKEROMA,
619 A., WALL, C., MITCHELL, E. A., CRENGLE, S., TRENHOLME, A., CRANE, J. &
620 CAMARGO, C. A., JR. 2014. Vitamin D during pregnancy and infancy and infant
621 serum 25-hydroxyvitamin D concentration. *Pediatrics*, 133, e143-53.

622 GRAY, T. K., LESTER, G. E. & LORENC, R. S. 1979. Evidence for extra-renal 1 alpha-
623 hydroxylation of 25-hydroxyvitamin D₃ in pregnancy. *Science*, 204, 1311-3.

624 GREY, A. & BOLLAND, M. J. 2016. Inaccurate dissemination of the MAVIDOS trial
625 results. *Lancet Diabetes Endocrinol*, 4, 481.

626 GUVEN, A., ECEVIT, A., SOZER, O., TARCAN, A., TARCAN, A. & OZBEK, N. 2012.
627 Correlation between the cord vitamin D levels and regulatory T cells in newborn
628 infants. *Eur J Pediatr*, 171, 1161-6.

629 HADDOW, J. E., NEVEUX, L. M., PALOMAKI, G. E., LAMBERT-MESSERLIAN, G.,
630 CANICK, J. A., GRENACHE, D. G. & LU, J. 2011. The Relationship between PTH
631 and 25-Hydroxy Vitamin D Early in Pregnancy. *Clin Endocrinol (Oxf)*.

632 HAWRYLOWICZ, C. M. & SANTOS, A. F. 2019. Vitamin D: can the sun stop the atopic
633 epidemic? *Curr Opin Allergy Clin Immunol*.

634 HEANEY, R. P. 2014. Guidelines for optimizing design and analysis of clinical studies of
635 nutrient effects. *Nutr Rev*, 72, 48-54.

636 HEMMINGWAY, A., KENNY, L. C., MALVISI, L. & KIELY, M. E. 2018. Exploring the
637 concept of functional vitamin D deficiency in pregnancy: impact of the interaction
638 between 25-hydroxyvitamin D and parathyroid hormone on perinatal outcomes. *Am J*
639 *Clin Nutr*, 108, 821-9.

640 HEWISON, M. 2018. The earlier the better: preconception vitamin D and protection against
641 pregnancy loss. *Lancet Diabetes Endocrinol*, 6, 680-681.

642 HILLMAN, L. S., SALMONS, S. & DOKOH, S. 1985. Serum 1,25-dihydroxyvitamin D
643 concentrations in premature infants: preliminary results. *Calcif Tissue Int*, 37, 223-7.

644 HOFMEYR, G. J., BELIZÁN, J. M., VON DADELSZEN, P. & CALCIUM AND PRE-
645 ECLAMPSIA (CAP) STUDY GROUP 2014. Low-dose calcium supplementation for
646 preventing pre-eclampsia: a systematic review and commentary. *BJOG*, 121, 951-7.

647 HOLLIS, B. W. 2019. Vitamin D status during pregnancy: The importance of getting it right.
648 *EBioMedicine*, 39, 23-24.

649 HOLLIS, B. W., JOHNSON, D., HULSEY, T. C., EBELING, M. & WAGNER, C. L. 2011.
650 Vitamin D supplementation during pregnancy: Double blind, randomized clinical trial
651 of safety and effectiveness. *J Bone Miner Res*, 26, 2341-57.

652 HOLLIS, B. W. & PITTARD, W. B. 1984a. Evaluation of the total fetomaternal vitamin D
653 relationships at term: Evidence for racial differences. *J Clin Endocrinol Metab*, 59,
654 652-657.

655 HOLLIS, B. W. & PITTARD, W. B., 3RD 1984b. Evaluation of the total fetomaternal
656 vitamin D relationships at term: evidence for racial differences. *J Clin Endocrinol*
657 *Metab*, 59, 652-7.

658 HOLLIS, B. W. & WAGNER, C. L. 2013. Vitamin D and Pregnancy: Skeletal Effects,
659 Nonskeletal Effects, and Birth Outcomes. *Calcified tissue international*, 92, 128-39.

660 HOLLIS, B. W. & WAGNER, C. L. 2017a. New insights into the vitamin D requirements
661 during pregnancy. *Bone Res*, 5, 17030.

662 HOLLIS, B. W. & WAGNER, C. L. 2017b. Vitamin D supplementation during pregnancy:
663 Improvements in birth outcomes and complications through direct genomic alteration.
664 *Mol Cell Endocrinol*, 453, 113-130.

665 HORNSBY, E., PFEFFER, P. E., LARANJO, N., CRUIKSHANK, W., TUZOVA, M.,
666 LITONJUA, A. A., WEISS, S. T., CAREY, V. J., O'CONNOR, G. &
667 HAWRYLOWICZ, C. 2018. Vitamin D supplementation during pregnancy: Effect on
668 the neonatal immune system in a randomized controlled trial. *J Allergy Clin Immunol*,
669 141, 269-278 e1.

670 INSTITUTE OF MEDICINE 2011. Dietary reference intakes for Calcium and Vitamin D.
671 Washington (DC): National Academies Press.

672 JEFFERY, L. E., BURKE, F., MURA, M., ZHENG, Y., QURESHI, O. S., HEWISON, M.,
673 WALKER, L. S. K., LAMMAS, D. A., RAZA, K. & SANSOM, D. M. 2009. 1,25-
674 Dihydroxyvitamin D3 and IL-2 Combine to Inhibit T Cell Production of
675 Inflammatory Cytokines and Promote Development of Regulatory T Cells Expressing
676 CTLA-4 and FoxP3. *The Journal of Immunology*, 183, 5458-5467.

677 JI, J., ZHAI, H., ZHOU, H., SONG, S., MOR, G. & LIAO, A. 2019. The role and mechanism
678 of vitamin D-mediated regulation of Treg/Th17 balance in recurrent pregnancy loss.
679 *Am J Reprod Immunol*, 81, e13112.

680 KALUDJEROVIC, J. & VIETH, R. 2010. Relationship between vitamin D during perinatal
681 development and health. *J Midwifery Womens Health*, 55, 550-60.

682 KELLY, R. S., CHAWES, B. L., GUO, F., ZHANG, L., BLIGHE, K., LITONJUA, A. A.,
683 RABY, B. A., LEVY, B. D., RAGO, D., STOKHOLM, J., BONNELYKKE, K.,
684 BISGAARD, H., ZHOU, X., LASKY-SU, J. A. & WEISS, S. T. 2019. The role of the
685 17q21 genotype in the prevention of early childhood asthma and recurrent wheeze by
686 vitamin D. *Eur Respir J*, 54.

687 KIELY, M., HEMMINGWAY, A. & O'CALLAGHAN, K. M. 2017a. Vitamin D in
688 pregnancy: current perspectives and future directions. *Ther Adv Musculoskelet Dis*, 9,
689 145-54.

690 KIELY, M., O'DONOVAN, S. M., KENNY, L. C., HOURIHANE, J. O., IRVINE, A. D. &
691 MURRAY, D. M. 2017b. Vitamin D metabolite concentrations in umbilical cord
692 blood serum and associations with clinical characteristics in a large prospective
693 mother-infant cohort in Ireland. *J Steroid Biochem Mol Biol*, 167, 162-8.

694 KIELY, M. E., ZHANG, J. Y., KINSELLA, M., KHASHAN, A. S. & KENNY, L. C. 2016.
695 Vitamin D status is associated with uteroplacental dysfunction indicated by pre-
696 eclampsia and small-for-gestational-age birth in a large prospective pregnancy cohort
697 in Ireland with low vitamin D status. *Am J Clin Nutr*, 104, 354-61.

698 KNABL, J., VATTAI, A., YE, Y., JUECKSTOCK, J., HUTTER, S., KAINER, F.,
699 MAHNER, S. & JESCHKE, U. 2017. Role of Placental VDR Expression and
700 Function in Common Late Pregnancy Disorders. *Int J Mol Sci*, 18.

701 KOVACS, C. S. 2014. Bone development and mineral homeostasis in the fetus and neonate:
702 roles of the calciotropic and phosphotropic hormones. *Physiol Rev*, 94, 1143-218.

703 KWAK-KIM, J., SKARIAH, A., WU, L., SALAZAR, D., SUNG, N. & OTA, K. 2016.
704 Humoral and cellular autoimmunity in women with recurrent pregnancy losses and
705 repeated implantation failures: A possible role of vitamin D. *Autoimmun Rev*, 15, 943-
706 7.

707 LIPS, P., CASHMAN, K. D., LAMBERG-ALLARDT, C., BISCHOFF-FERRARI, H. A.,
708 OBERMAYER-PIETSCH, B. R., BIANCHI, M., STEPAN, J., EL-HAJJ
709 FULEIHAN, G. & BOUILLON, R. 2019. MANAGEMENT OF ENDOCRINE
710 DISEASE: Current vitamin D status in European and Middle East countries and

711 strategies to prevent vitamin D deficiency; a position statement of the European
712 Calcified Tissue Society. *Eur J Endocrinol*.

713 LITONJUA, A. A., CAREY, V. J., LARANJO, N., HARSHFIELD, B. J., MCEL RATH, T.
714 F., O'CONNOR, G. T., SANDEL, M., IVERSON, R. E., JR., LEE-PARITZ, A.,
715 STRUNK, R. C., BACHARIER, L. B., MACONES, G. A., ZEIGER, R. S.,
716 SCHATZ, M., HOLLIS, B. W., HORNSBY, E., HAWRYLOWICZ, C., WU, A. C. &
717 WEISS, S. T. 2016. Effect of Prenatal Supplementation With Vitamin D on Asthma
718 or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized
719 Clinical Trial. *JAMA*, 315, 362-70.

720 LITONJUA, A. A., CAREY, V. J., LARANJO, N., STUBBS, B. J., MIRZAKHANI, H.,
721 O'CONNOR, G. T., SANDEL, M., BEIGELMAN, A., BACHARIER, L. B.,
722 ZEIGER, R. S., SCHATZ, M., HOLLIS, B. W. & WEISS, S. T. 2020. Six-Year
723 Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. *N Engl J Med*,
724 382, 525-533.

725 LIU, N. Q. & HEWISON, M. 2012. Vitamin D, the placenta and pregnancy. *Arch Biochem*
726 *Biophys*, 523, 37-47.

727 LIU, N. Q., KAPLAN, A. T., LAGISHETTY, V., OUYANG, Y. B., OUYANG, Y.,
728 SIMMONS, C. F., EQUILS, O. & HEWISON, M. 2011. Vitamin D and the
729 regulation of placental inflammation. *Journal of immunology*, 186, 5968-74.

730 LIU, N. Q., OUYANG, Y., BULUT, Y., LAGISHETTY, V., CHAN, S. Y., HOLLIS, B. W.,
731 WAGNER, C., EQUILS, O. & HEWISON, M. 2013. Dietary vitamin D restriction in
732 pregnant female mice is associated with maternal hypertension and altered placental
733 and fetal development. *Endocrinology*, 154, 2270-80.

734 LIU, P. T., STENGER, S., LI, H., WENZEL, L., TAN, B. H., KRUTZIK, S. R., OCHOA, M.
735 T., SCHAUBER, J., WU, K., MEINKEN, C., KAMEN, D. L., WAGNER, M., BALS,
736 R., STEINMEYER, A., ZUGEL, U., GALLO, R. L., EISENBERG, D., HEWISON,
737 M., HOLLIS, B. W., ADAMS, J. S., BLOOM, B. R. & MODLIN, R. L. 2006. Toll-
738 like receptor triggering of a vitamin D-mediated human antimicrobial response.
739 *Science*, 311, 1770-3.

740 MACDONALD, C., UPTON, T., HUNT, P., PHILLIPS, I., KAUFMANN, M.,
741 FLORKOWSKI, C., SOULE, S. & JONES, G. 2020. Vitamin D supplementation in
742 pregnancy: A word of caution. Familial hypercalcaemia due to disordered vitamin D
743 metabolism. *Ann Clin Biochem*, 4563219897691.

744 MARCH, K. M., CHEN, N. N., KARAKOCHUK, C. D., SHAND, A. W., INNIS, S. M.,
745 VON DADELSZEN, P., BARR, S. I., LYON, M. R., WHITING, S. J., WEILER, H.
746 A. & GREEN, T. J. 2015. Maternal vitamin D₃ supplementation at 50 ug/d protects
747 against low serum 25-hydroxyvitamin D in infants at 8 wk of age: a randomized
748 controlled trial of 3 doses of vitamin D beginning in gestation and continued in
749 lactation. *Am J Clin Nutr*, 102, 402-10.

750 MCDONNELL, S. L., BAGGERLY, K. A., BAGGERLY, C. A., ALIANO, J. L., FRENCH,
751 C. B., BAGGERLY, L. L., EBELING, M. D., RITTENBERG, C. S., GOODIER, C.
752 G., MATEUS NINO, J. F., WINELAND, R. J., NEWMAN, R. B., HOLLIS, B. W. &
753 WAGNER, C. L. 2017. Maternal 25(OH)D concentrations ≥ 40 ng/mL associated
754 with 60% lower preterm birth risk among general obstetrical patients at an urban
755 medical center. *PLoS One*, 12, e0180483.

756 MIRZAKHANI, H., LITONJUA, A. A., MCEL RATH, T. F., O'CONNOR, G., LEE-
757 PARRITZ, A., IVERSON, R., MACONES, G., STRUNK, R. C., BACHARIER, L.
758 B., ZEIGER, R., HOLLIS, B. W., HANDY, D. E., SHARMA, A., LARANJO, N.,
759 CAREY, V., QIU, W., SANTOLINI, M., LIU, S., CHHABRA, D.,
760 ENQUOBAHRIE, D. A., WILLIAMS, M. A., LOSCALZO, J. & WEISS, S. T. 2016.

761 Early pregnancy vitamin D status and risk of preeclampsia. *J Clin Invest*, 126, 4702-
762 4715.

763 MOR, G. & CARDENAS, I. 2010. The immune system in pregnancy: a unique complexity.
764 *Am J Reprod Immunol*, 63, 425-33.

765 MUNNS, C. F., SHAW, N., KIELY, M., SPECKER, B. L., THACHER, T. D., OZONO, K.,
766 MICHIGAMI, T., TIOSANO, D., MUGHAL, M. Z., MÄKITIE, O., RAMOS-
767 ABAD, L., WARD, L., DIMEGLIO, L. A., ATAPATTU, N., CASSINELLI, H.,
768 BRAEGGER, C., PETTIFOR, J. M., SETH, A., IDRIS, H. W., BHATIA, V., FU, J.,
769 GOLDBERG, G., SÄVENDAHL, L., KHADGAWAT, R., PLUDOWSKI, P.,
770 MADDOCK, J., HYPÖNEN, E., ODUWOLE, A., FREW, E., AGUIAR, M.,
771 TULCHINSKY, T., BUTLER, G. & HÖGLER, W. 2016. Global consensus
772 recommendations on prevention and management of nutritional rickets. *J Clin*
773 *Endocrinol Metab*, 101, 394-415.

774 NAGHSHINEH, E. & SHEIKHALIYAN, S. 2016. Effect of vitamin D supplementation in
775 the reduce risk of preeclampsia in nulliparous women. *Adv Biomed Res*, 5, 7.

776 NIKOLIC, T. & ROEP, B. O. 2013. Regulatory multitasking of tolerogenic dendritic cells -
777 lessons taken from vitamin d3-treated tolerogenic dendritic cells. *Front Immunol*, 4,
778 113.

779 NOVAKOVIC, B., SIBSON, M., NG, H. K., MANUELPIILLAI, U., RAKYAN, V., DOWN,
780 T., BECK, S., FOURNIER, T., EVAIN-BRION, D., DIMITRIADIS, E., CRAIG, J.
781 M., MORLEY, R. & SAFFERY, R. 2009. Placenta-specific methylation of the
782 vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active
783 vitamin D levels at the fetomaternal interface. *J Biol Chem*, 284, 14838-48.

784 O'CALLAGHAN, K. M., HENNESSY, Á., HULL, G. L. J., HEALY, K., RITZ, C., KENNY,
785 L. C., CASHMAN, K. D. & KIELY, M. E. 2018. Estimation of the maternal vitamin
786 D intake that maintains circulating 25-hydroxyvitamin D in late gestation at a
787 concentration sufficient to keep umbilical cord sera ≥ 25 -30 nmol/L: a dose-response,
788 double-blind, randomized placebo-controlled trial in pregnant women at northern
789 latitude. *Am J Clin Nutr*, 108, 77-91.

790 OLMOS-ORTIZ, A., AVILA, E., DURAND-CARBAJAL, M. & DIAZ, L. 2015. Regulation
791 of calcitriol biosynthesis and activity: focus on gestational vitamin D deficiency and
792 adverse pregnancy outcomes. *Nutrients*, 7, 443-80.

793 PALACIOS, C., KOSTIUK, L. K. & PENA-ROSAS, J. P. 2019a. Vitamin D
794 supplementation for women during pregnancy. *Cochrane Database Syst Rev*, 7,
795 CD008873.

796 PALACIOS, C., TRAK-FELLERMEIER, M. A., MARTINEZ, R. X., LOPEZ-PEREZ, L.,
797 LIPS, P., SALISI, J. A., JOHN, J. C. & PENA-ROSAS, J. P. 2019b. Regimens of
798 vitamin D supplementation for women during pregnancy. *Cochrane Database Syst*
799 *Rev*, 10, CD013446.

800 PAPAPETROU, P. D. 2010. The interrelationship of serum 1,25-dihydroxyvitamin D, 25-
801 hydroxyvitamin D and 24,25-dihydroxyvitamin D in pregnancy at term: a meta-
802 analysis. *Hormones (Athens)*, 9, 136-44.

803 PENNA, G., AMUCHASTEGUI, S., GIARRATANA, N., DANIEL, K. C., VULCANO, M.,
804 SOZZANI, S. & ADORINI, L. 2007. 1,25-Dihydroxyvitamin D3 Selectively
805 Modulates Tolerogenic Properties in Myeloid but Not Plasmacytoid Dendritic Cells.
806 *The Journal of Immunology*, 178, 145-153.

807 PENNA, G., RONCARI, A., AMUCHASTEGUI, S., DANIEL, K. C., BERTI, E.,
808 COLONNA, M. & ADORINI, L. 2005. Expression of the inhibitory receptor ILT3 on
809 dendritic cells is dispensable for induction of CD4⁺Foxp3⁺ regulatory T cells by
810 1,25-dihydroxyvitamin D3. *Blood*, 106, 3490-7.

811 PFEFFER, P. E. & HAWRYLOWICZ, C. M. 2018. Vitamin D in Asthma: Mechanisms of
812 Action and Considerations for Clinical Trials. *Chest*, 153, 1229-1239.

813 POWE, C. E., SEELY, E. W., RANA, S., BHAN, I., ECKER, J., KARUMANCHI, S. A. &
814 THADHANI, R. 2010. First Trimester Vitamin D, Vitamin D Binding Protein, and
815 Subsequent Preeclampsia. *Hypertension*, HYPERTENSIONAHA.110.158238.

816 PRENTICE, A. 2013. Nutritional rickets around the world. *J Steroid Biochem Mol Biol*, 136,
817 201-6.

818 RACICOT, K., KWON, J. Y., ALDO, P., SILASI, M. & MOR, G. 2014. Understanding the
819 complexity of the immune system during pregnancy. *Am J Reprod Immunol*, 72, 107-
820 16.

821 RITCHIE, L. D., FUNG, E. B., HALLORAN, B. P., TURNLUND, J. R., VAN LOAN, M.
822 D., CANN, C. E. & KING, J. C. 1998. A longitudinal study of calcium homeostasis
823 during human pregnancy and lactation and after resumption of menses. *Am J Clin*
824 *Nutr*, 67, 693-701.

825 ROBINSON, C. J., ALANIS, M. C., WAGNER, C. L., HOLLIS, B. W. & JOHNSON, D. D.
826 2010. Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. *Am J*
827 *Obstet Gynecol*, 203, 366 e1-6.

828 ROSTAMI, M., RAMEZANI TEHRANI, F., SIMBAR, M., BIDHENDI YARANDI, R.,
829 MINOOEE, S., HOLLIS, B. W. & HOSSEINPANAH, F. 2018. Effectiveness of
830 prenatal vitamin D deficiency screening and treatment program: a stratified
831 randomized field trial. *J Clin Endocrinol Metab*.

832 ROTH, D. E., ABRAMS, S. A., ALOIA, J., BERGERON, G., BOURASSA, M. W.,
833 BROWN, K. H., CALVO, M. S., CASHMAN, K. D., COMBS, G., DE-REGIL, L.
834 M., JEFFERDS, M. E., JONES, K. S., KAPNER, H., MARTINEAU, A. R.,
835 NEUFELD, L. M., SCHLEICHER, R. L., THACHER, T. D. & WHITING, S. J.
836 2018a. Global prevalence and disease burden of vitamin D deficiency: a roadmap for
837 action in low- and middle-income countries. *Ann N Y Acad Sci*, 1430, 44-79.

838 ROTH, D. E., LEUNG, M., MESFIN, E., QAMAR, H., WATTERWORTH, J. & PAPP, E.
839 2017. Vitamin D supplementation during pregnancy: state of the evidence from a
840 systematic review of randomised trials. *BMJ*, 359, j5237.

841 ROTH, D. E., MORRIS, S. K., ZLOTKIN, S., GERNAND, A. D., AHMED, T., SHANTA,
842 S. S., PAPP, E., KORSIK, J., SHI, J., ISLAM, M. M., JAHAN, I., KEYA, F. K.,
843 WILLAN, A. R., WEKSBERG, R., MOHSIN, M., RAHMAN, Q. S., SHAH, P. S.,
844 MURPHY, K. E., STIMEC, J., PELL, L. G., QAMAR, H. & AL MAHMUD, A.
845 2018b. Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth. *N*
846 *Engl J Med*, 379, 535-546.

847 SABLOK, A., BATRA, A., THARIANI, K., BATRA, A., BHARTI, R., AGGARWAL, A.
848 R., KABI, B. C. & CHELLANI, H. 2015. Supplementation of vitamin D in pregnancy
849 and its correlation with fetomaternal outcome. *Clin Endocrinol (Oxf)*, 83, 536-41.

850 SARAFIN, K., DURAZO-ARVIZU, R., TIAN, L., PHINNEY, K. W., TAI, S., CAMARA, J.
851 E., MERKEL, J., GREEN, E., SEMPOS, C. T. & BROOKS, S. P. 2015.
852 Standardizing 25-hydroxyvitamin D values from the Canadian Health Measures
853 Survey. *Am J Clin Nutr*, 102, 1044-50.

854 SCHLEICHER, R. L., STERNBERG, M. R., LOOKER, A. C., YETLEY, E. A., LACHER,
855 D. A., SEMPOS, C. T., TAYLOR, C. L., DURAZO-ARVIZU, R. A., MAW, K. L.,
856 CHAUDHARY-WEBB, M., JOHNSON, C. L. & PFEIFFER, C. M. 2016. National
857 estimates of serum total 25-hydroxyvitamin D and metabolite concentrations
858 measured by liquid chromatography-tandem mass spectrometry in the US population
859 during 2007-2010. *J Nutr*, 146, 1051-61.

860 SCHULZ, E. V., CRUZE, L., WEI, W., GEHRIS, J. & WAGNER, C. L. 2017. Maternal
861 vitamin D sufficiency and reduced placental gene expression in angiogenic
862 biomarkers related to comorbidities of pregnancy. *J Steroid Biochem Mol Biol*.
863 SEKI, K., FURUYA, K., MAKIMURA, N., MITSUI, C., HIRATA, J. & NAGATA, I. 1994.
864 Cord blood levels of calcium-regulating hormones and osteocalcin in premature
865 infants. *J Perinat Med*, 22, 189-94.
866 SHARIF, K., SHARIF, Y., WATAD, A., YAVNE, Y., LICHTBROUN, B., BRAGAZZI, N.
867 L., AMITAL, H. & SHOENFELD, Y. 2018. Vitamin D, autoimmunity and recurrent
868 pregnancy loss: More than an association. *Am J Reprod Immunol*, 80, e12991.
869 SHUB, A. & MCCARTHY, E. A. 2019. Letter to the Editor: "Effectiveness of Prenatal
870 Vitamin D Deficiency Screening and Treatment Program: A Stratified Randomized
871 Field Trial". *J Clin Endocrinol Metab*, 104, 337-338.
872 STUKES, T. M., SHARY, J. R., WEI, W., EBELING, M. D., DEZSI, K. B., SHARY, F. S.,
873 FORESTIERI, N. E., HOLLIS, B. W. & WAGNER, C. L. 2016. Circulating
874 Cathelicidin Concentrations in a Cohort of Healthy Children: Influence of Age, Body
875 Composition, Gender and Vitamin D Status. *PLoS One*, 11, e0152711.
876 SUDFELD, C. R. & SMITH, E. R. 2019. New Evidence Should Inform WHO Guidelines on
877 Multiple Micronutrient Supplementation in Pregnancy. *J Nutr*, 149, 359-361.
878 TAMBLYN, J. A., HEWISON, M., WAGNER, C. L., BULMER, J. N. & KILBY, M. D.
879 2015. Immunological role of vitamin D at the maternal-fetal interface. *J Endocrinol*,
880 224, R107-21.
881 TAMBLYN, J. A., JENKINSON, C., LARNER, D. P., HEWISON, M. & KILBY, M. D.
882 2018. Serum and urine vitamin D metabolite analysis in early preeclampsia. *Endocr*
883 *Connect*, 7, 199-210.
884 THACHER, T. D., FISCHER, P. R., STRAND, M. A. & PETTIFOR, J. M. 2006. Nutritional
885 rickets around the world: causes and future directions. *Ann Trop Paediatr*, 26, 1-16.
886 TOUS, M., VILLALOBOS, M., IGLESIAS, L., FERNANDEZ-BARRES, S. & ARIJA, V.
887 2019. Vitamin D status during pregnancy and offspring outcomes: a systematic
888 review and meta-analysis of observational studies. *Eur J Clin Nutr*.
889 TSUPRYKOV, O., BUSE, C., SKOBLO, R. & HOCHER, B. 2019. Comparison of free and
890 total 25-hydroxyvitamin D in normal human pregnancy. *The Journal of Steroid*
891 *Biochemistry and Molecular Biology*, 190, 29-36.
892 URRY, Z., CHAMBERS, E. S., XYSTRAKIS, E., DIMELOE, S., RICHARDS, D. F.,
893 GABRYŠOVÁ, L., CHRISTENSEN, J., GUPTA, A., SAGLANI, S., BUSH, A.,
894 O'GARRA, A., BROWN, Z. & HAWRYLOWICZ, C. M. 2012. The role of 1 α ,25-
895 dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3⁺ and IL-
896 10⁺CD4⁺T cells. *European Journal of Immunology*, 42, 2697-2708.
897 VAN DER AAR, A. M. G., SIBIRYAK, D. S., BAKDASH, G., VAN CAPEL, T. M. M.,
898 VAN DER KLEIJ, H. P. M., OPSTELTEN, D.-J. E., TEUNISSEN, M. B. M.,
899 KAPSENBERG, M. L. & DE JONG, E. C. 2011. Vitamin D3 targets epidermal and
900 dermal dendritic cells for induction of distinct regulatory T cells. 127, 1532-1540.e7.
901 VASILIOU, J. E., LUI, S., WALKER, S. A., CHOCHAN, V., XYSTRAKIS, E., BUSH, A.,
902 HAWRYLOWICZ, C. M., SAGLANI, S. & LLOYD, C. M. 2014. Vitamin D
903 deficiency induces Th2 skewing and eosinophilia in neonatal allergic airways disease.
904 *Allergy*, 69, 1380-9.
905 VIJAYENDRA CHARY, A., HEMALATHA, R., SESHACHARYULU, M., VASUDEVA
906 MURALI, M., JAYAPRAKASH, D. & DINESH KUMAR, B. 2015a. Reprint of
907 "Vitamin D deficiency in pregnant women impairs regulatory T cell function". *J*
908 *Steroid Biochem Mol Biol*, 148, 194-201.

909 VIJAYENDRA CHARY, A., HEMALATHA, R., SESHACHARYULU, M., VASUDEVA
910 MURALI, M., JAYAPRAKASH, D. & DINESH KUMAR, B. 2015b. Vitamin D
911 deficiency in pregnant women impairs regulatory T cell function. *J Steroid Biochem*
912 *Mol Biol*, 147, 48-55.

913 WAGNER, C. L. & HOLLIS, B. W. 2011. Beyond PTH: assessing vitamin D status during
914 early pregnancy. *Clinical Endocrinology*, 75, 285-6.

915 WAGNER, C. L., MCNEIL, R., HAMILTON, S. A., WINKLER, J., RODRIGUEZ COOK,
916 C., WARNER, G., BIVENS, B., DAVIS, D. J., SMITH, P. G., MURPHY, M.,
917 SHARY, J. R. & HOLLIS, B. W. 2013a. A randomized trial of vitamin D
918 supplementation in 2 community health center networks in South Carolina. *Am J*
919 *Obstet Gynecol*, 208, 137 e1-137 e13.

920 WAGNER, C. L., MCNEIL, R. B., JOHNSON, D. D., HULSEY, T. C., EBELING, M.,
921 ROBINSON, C., HAMILTON, S. A. & HOLLIS, B. W. 2013b. Health characteristics
922 and outcomes of two randomized vitamin D supplementation trials during pregnancy:
923 a combined analysis. *J Steroid Biochem Mol Biol*, 136, 313-20.

924 WEISS, S., WOLSK, H., MIRZAKHANI, H., HOLLIS, B., CAREY, V., LITONJUA, A. &
925 GROUP., F. T. V. T. Asthma/Wheeze and preeclampsia outcomes in the VDAART
926 Trial: The influence of baseline and treatment levels of vitamin D on treatment
927 response. The Vitamin D Workshop, March 29-31, 2016 2016 Boston, MA.
928 www.vitamindworkshop.org.

929 WEISS, S. T. & LITONJUA, A. A. 2017. Vitamin D in Host Defense: Implications for
930 Future Research. *Am J Respir Cell Mol Biol*, 56, 692-693.

931 WHITEHEAD, M., LANE, G., YOUNG, O., CAMPBELL, S., ABEYASEKERA, G.,
932 HILLYARD, C. J., MACINTYRE, I., PHANG, K. G. & STEVENSON, J. C. 1981.
933 Interrelations of calcium-regulating hormones during normal pregnancy. *Br Med J*
934 *(Clin Res Ed)*, 283, 10-2.

935 WOLSK, H. M., CHAWES, B. L., LITONJUA, A. A., HOLLIS, B. W., WAAGE, J.,
936 STOKHOLM, J., BONNELYKKE, K., BISGAARD, H. & WEISS, S. T. 2017a.
937 Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early
938 childhood: A combined analysis of two randomized controlled trials. *PLoS One*, 12,
939 e0186657.

940 WOLSK, H. M., HARSHFIELD, B. J., LARANJO, N., CAREY, V. J., O'CONNOR, G.,
941 SANDEL, M., STRUNK, R. C., BACHARIER, L. B., ZEIGER, R. S., SCHATZ, M.,
942 HOLLIS, B. W., WEISS, S. T. & LITONJUA, A. A. 2017b. Vitamin D
943 supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma
944 or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal
945 Asthma Reduction Trial. *J Allergy Clin Immunol*, 140, 1423-1429 e5.

946 WORLD HEALTH ORGANIZATION 2016. WHO recommendations on antenatal care for a
947 positive pregnancy experience. Geneva: World Health Organization.

948 WU, L., KWAK-KIM, J., ZHANG, R., LI, Q., LU, F. T., ZHANG, Y., WANG, H. Y.,
949 ZHONG, L. W. & LIU, Y. S. 2018. Vitamin D level affects IVF outcome partially
950 mediated via Th/Tc cell ratio. *Am J Reprod Immunol*, 80, e13050.

951 YUAN, Y., TAI, W., XU, P., FU, Z., WANG, X., LONG, W., GUO, X., JI, C., ZHANG, L.,
952 ZHANG, Y. & WEN, J. 2019. Association of maternal serum 25-hydroxyvitamin D
953 concentrations with risk of preeclampsia: a nested case-control study and meta-
954 analysis. *J Matern Fetal Neonatal Med*, 1-10.

955 ZAHRAN, A. M., ZHARAN, K. M. & HETTA, H. F. 2018. Significant correlation between
956 regulatory T cells and vitamin D status in term and preterm labor. *J Reprod Immunol*,
957 129, 15-22.

958 ZHANG, Q., CHENG, Y., HE, M., LI, T., MA, Z. & CHENG, H. 2016. Effect of various
959 doses of vitamin D supplementation on pregnant women with gestational diabetes
960 mellitus: A randomized controlled trial. *Exp Ther Med*, 12, 1889-1895.
961 ZHOU, S. S., TAO, Y. H., HUANG, K., ZHU, B. B. & TAO, F. B. 2017. Vitamin D and risk
962 of preterm birth: Up-to-date meta-analysis of randomized controlled trials and
963 observational studies. *J Obstet Gynaecol Res*, 43, 247-256.

964

965

966 **Table 1. Factors Affecting Clinical Outcomes of Vitamin D Supplementation Trials**
 967 **during Pregnancy**

968

<ul style="list-style-type: none"> • Timing of intervention: when in gestation did supplementation occur
<ul style="list-style-type: none"> • Sample size
<ul style="list-style-type: none"> • Baseline serum 25(OH)D: e.g., the most profound effects of early supplementation seen in those with the lowest 25(OH)D concentrations at baseline
<ul style="list-style-type: none"> • Sunshine exposure
<ul style="list-style-type: none"> • Habitual vitamin D and calcium intake
<ul style="list-style-type: none"> • Race/ethnicity
<ul style="list-style-type: none"> • VDBP genotype
<ul style="list-style-type: none"> • Dosing frequency of vitamin D: daily vs. weekly vs. monthly dosing
<ul style="list-style-type: none"> • Adherence to dosing regimen
<ul style="list-style-type: none"> • Types of assays used to measure 25(OH)D concentration
<ul style="list-style-type: none"> • Type of analysis—<i>Intention-to-treat vs. per protocol</i>
<ul style="list-style-type: none"> • Biomarker used for vitamin D status: Is total circulating 25(OH)D concentration really the biomarker of what is going on at the cellular level during pregnancy? Should free 25(OH)D be measured? This is a question that comes up frequently.

969

970

971

972

973 **Table 2. Characteristics and primary findings of five randomized controlled trials of**
 974 **prenatal vitamin D supplementation***

	Hollis 2011(Hollis et al., 2011)	Litonjua 2016 (VDAART)(Litonjua et al., 2016)	Cooper 2016 (MAVID OS) (Cooper et al., 2016)	Chawes 2016 (COPSAC)(Chawes et al., 2016)	Roth 2018 (MDIG)(Roth et al., 2018b)
Country	USA	USA	UK	Denmark	Bangladesh
Total N randomized	502	881	1134	623	1300
Highest vitamin D dose	4000 IU/day	4400 IU/day	1000 IU/day	2800 IU/day	4000 IU/day (given as 28,000 IU/week)
Control group vitamin D dose	400 IU/day	400 IU/day	Placebo	400 IU/day	Placebo
Primary outcome measure	Serum 25(OH)D concentration	Early-childhood asthma or recurrent wheeze	Neonatal bone mass	Early-childhood persistent wheeze	Infant length (at one year of age)
Effect of vitamin D on primary outcome	Strong positive effect	No significant effect	No significant effect	No significant effect	No significant effect

975


976 *Trials selected if they were double-blind and enrolled >500 participants.

977

978

979

Relationship of 25(OH)D and 1,25(OH)₂D during Pregnancy



$$1,25(\text{OH})_2\text{D} = 291.23 * (1 - \exp(-0.0243 * 25(\text{OH})\text{D}))$$

980

981 **Figure 1. Substrate-Product Relationships of Vitamin D Metabolites during Pregnancy.**


982 This panel demonstrates the relationship circulating 25(OH)D to control the production of
983 1,25(OH)₂D during pregnancy. All data points for all subjects in all groups were included in
984 this analysis.

985 (from Hollis et al, 2011, Figure 3b Panel b, with permission (Hollis, 2011))

986

987

988



989

990

991

992 **Figure 2. Schematic representation of the advantages and disadvantages of approaches**
993 **available to investigators when analyzing data from a randomized controlled trial.** The
994 horizontal axis reflects the spectrum of choices related to the participant selection criteria. For
995 example, a discrete sub-group analysis may involve restriction to participants with baseline
996 25(OH)D<30 nmol/L, whereas population-representative sampling would include all
997 participants irrespective of baseline characteristics, adherence, or other non-random factors.
998 The vertical axis reflects the spectrum of choices related to the assignment of the exposure
999 variable. An intention-to-treat approach entails direct comparisons of the experimental versus
1000 control groups, relying only on the random assignment regardless of adherence or
1001 completeness of follow-up; in contrast, observational analyses usually ignore the random
1002 allocation and instead examine the association between an outcome and a non-random
1003 indicator of vitamin D status (e.g., 25(OH)D or number of vitamin D doses received).

1004

1005